Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Glioma × encorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 6 Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Skin Neoplasms 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 21 Bevacizumab 10 Radiotherapy 5 Irinotecan 5 Carmustine 4 Topotecan 3 Magnetic Resonance Spectroscopy 3 Magnetic Resonance Imaging 3 Carboplatin 3 Aminolevulinic Acid 3 ribociclib 2 poly ICLC 2 fluoromisonidazole 2 fluorodopa F 18 2 carmustine, poliferprosan 20 drug combination 2 cabozantinib 2 TIC10 compound 2 Surgical Procedures, Operative 2 Standard of Care 2 Re-Irradiation 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Panobinostat 2 O(6)-benzylguanine 2 Melphalan 2 Lomustine 2 Lacosamide 2 Filgrastim 2 Erlotinib Hydrochloride 2 Dynamic Contrast Enhanced Magnetic Resonance Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡